Summary of DIA Workshop: Comparability Challenges: Regulatory and Scientific Issues in the Assessment of Biopharmaceuticals

被引：7

作者：

Lewis, Richard M. ^{[1
]}

Cosenza, Mary Ellen ^{[1
]}

机构：

[1] Amgen Inc, Regulatory Affairs, Thousand Oaks, CA USA

来源：

DRUG INFORMATION JOURNAL | 2010年 / 44卷 / 04期

关键词：

Comparability; Regulatory; Biological product; Pharmacokinetics; Pharmacodynamics; Biochemical; Analyses; MONOCLONAL-ANTIBODY; GLYCOSYLATION; PHARMACOKINETICS; PANITUMUMAB; RECEPTOR;

D O I：

10.1177/009286151004400413

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

On February 3-4, 2009, a DIA Workshop was held to review and discuss comparability challenges and issues for biotechnology-derived pharmaceuticals. The workshop was held in the Washington, DC, area and was attended by representatives from the FDA and biotech and pharmaceutical industries. The expectation was to develop a consensus on which data are necessary to provide assurance of comparability for manufacturing changes made to biotechnology products during different stages of development or postmarketing. Numerous case studies were reviewed and discussed to build on best practices and recognize successful approaches to comparability.

引用

页码：485 / 504

页数：20

共 25 条

[21] The influence of regulatory framework on environmental impact assessment in the development of offshore wind farms in Spain: Issues, challenges and solutions
Salvador, Santiago
Gimeno, Luis
Sanz Larruga, F. Javier
OCEAN & COASTAL MANAGEMENT, 2018, 161 : 165 - 176
[22] Insect biocontrol with non-endemic entomopathogenic nematodes (Steinernema and Heterorhabditis spp): Conclusions and recommendations of a combined OECD and COST Workshop on Scientific and Regulatory Policy Issues
Ehlers, RU
Hokkanen, HMT
BIOCONTROL SCIENCE AND TECHNOLOGY, 1996, 6 (03) : 295 - 302
[23] Juvenile Toxicity Assessment of Anidulafungin in Rats: An Example of Navigating Case-by-Case Study Design Through Scientific and Regulatory Challenges
Bowman, Christopher J.
Chmielewski, Gary
Lewis, Elise
Ripp, Sharon
Sawaryn, Christopher M.
Cross, David M.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2011, 92 (04) : 333 - 344
[24] Generic Drugs Face Regulatory and Scientific Challenges FDA funds research to further development of innovative generics, while working to address review and approval issues
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2013, 26 (08) : 10 - 11
[25] Food and feed chemical contaminants in the European Union: Regulatory, scientific, and technical issues concerning chemical contaminants occurrence, risk assessment, and risk management in the European Union
Silano, Marco
Silano, Vittorio
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2017, 57 (10) : 2162 - 2217

← 1 2 3 →